Encellin raises about $10M for type 1 diabetes cell replacement therapy

Encellin raised $9.9 million to join the burgeoning type 1 diabetes space with its own cell replacement therapy and first-in-human data expected next year.

The small team at the San Francisco-based company employs fewer than five people, who developed what they call encapsulated cell replacement therapy (EnCRT) – a porous…
Click here to view original post